Open report — full analysis, no account required.
Sign up to generate reports and read filings that aren't on the open list.
Get notified when BBLG files again. Create a free account and we'll email you the moment its next filing is analyzed.
Get filing alertsBone Biologics raises $3M, extends runway through Q2 2027
Filed July 23, 2026 · Period ending July 23, 2026 · ~1 min read
Key Changes
-
high
Completed $3M private placement with one institutional investor in July 2026; warrants could provide up to $6M more if exercised. Proceeds fund clinical trials, patent work, and general corporate purposes.
Exhibit 99.1 view on EDGAR → -
high
Management believes the financing extends operating runway through Q2 2027 without requiring near-term additional capital.
Exhibit 99.1 view on EDGAR → -
medium
Validated shelf life of rhNELL-1 protein extended to 29 months in May 2026, up from 24 months in December 2025, supporting manufacturing flexibility.
Exhibit 99.1 view on EDGAR → -
medium
Expects to complete patient enrollment in first-in-human NB1 pilot study by year-end 2026, consistent with January guidance.
Exhibit 99.1 view on EDGAR →
Summary
Bone Biologics disclosed a $3 million private placement completed in July 2026 with a single healthcare-focused institutional investor. The deal included Series F and Series G warrants that could provide up to $6 million in additional proceeds if exercised, though exercise is not assured.
Management believes the financing extends the company's operating runway through the second quarter of 2027, allowing it to fund clinical trials, patent maintenance, and operations without near-term reliance on additional capital. The company also reported that the validated shelf life of its rhNELL-1 protein reached 29 months in May 2026, up from 24 months six months earlier.
This extension supports manufacturing and supply chain planning as the program advances. Patient enrollment in the first-in-human pilot study of NB1 is expected to complete by year-end 2026, on track with prior guidance. For a pre-revenue biotech, the financing provides near-term visibility into cash runway and clinical execution.
Section-by-Section Diff
Event · Item 7.01 — Regulation FD Disclosure
Bone Biologics issued a press release highlighting corporate, scientific and operational milestones progress across 2026 priorities.
Show 1 minor / wording change
Added in current filing · verify on EDGAR →
On July 23, 2026, Bone Biologics Corporation (the “Company”) issued a press release highlighting the corporate, scientific and operational milestones progress across 2026 priorities.
The company issued a press release summarizing progress on its 2026 corporate, scientific, and operational priorities. The 8-K does not disclose the specific milestones or achievements; it only announces that a press release was issued and furnishes it as an exhibit. This is a Regulation FD disclosure, meaning the information is being made publicly available to all investors simultaneously.
Event · Exhibit 99.1
Bone Biologics completed $3M private placement, extended rhNELL-1 shelf life to 29 months, and expects to complete patient enrollment by year-end.
Added in current filing · view on EDGAR →
The Company believes this financing extends its operating runway through Q2 2027, providing the capital base to execute the clinical and operational priorities set out at the start of the year without near-term reliance on additional financing.
Management believes the July 2026 financing provides sufficient capital to fund operations through the second quarter of 2027. This runway is intended to support clinical trials, patent work, and operational priorities without requiring additional near-term financing.
Added in current filing · view on EDGAR →
In May 2026, the Company announced that the validated shelf life of its rhNELL-1 protein had been extended to 29 months, building on the 24-month milestone achieved in December 2025.
The validated shelf life of the company's rhNELL-1 protein was extended to 29 months in May 2026, up from 24 months achieved in December 2025. Management believes this extended stability supports manufacturing flexibility and supply chain planning as the program advances.
Thanks — your feedback helps us improve report quality.
Figures/quotes linked to EDGAR · Narrative written by AI · Jul 28, 2026 · How we verify